Willa D Brenowitz

Epidemiology | Brain Aging Research
@KPCHR

[Willa D Brenowitz @WillaBrenowitz]

Our study on vision impairment, eye conditions, and dementia was published by @JAMANetworkOpen! Excellent work by @ErinL_Ferguson using Mendelian randomization and neuroimaging in UK Biobank. Findings support cataracts as a risk factor for dementia, especially vascular dementia.

[JAMA Network Open @JAMANetworkOpen]

Cataracts were associated with increased risk of dementia, especially vascular dementia, and reduced total brain volumes in this study. These findings lend further support to the hypothesis that cataract extraction may reduce the risk for dementia. https://t.co/JfTjIpmV6P

[Willa D Brenowitz @WillaBrenowitz]

Check out our paper on AD genetic risk and MRI volumes across age. Great work led by by Peter Buto!

We found higher AD genetic risk was associated with reduced volumes as early as age 50 for several regions, incl hippocampus. AD begins in midlife?

https://t.co/OuNhM0OW1U

[Willa D Brenowitz @WillaBrenowitz]

Deadline is now extended to Sep 15th!

[Willa D Brenowitz @WillaBrenowitz]

Paper Call for Special Issue on Sensory Changes and Alzheimer’s Disease and Related Dementias!

Deadline Aug 15th

https://t.co/WBbLM2Dvde

[Willa D Brenowitz @WillaBrenowitz]

Paper Call for Special Issue on Sensory Changes and Alzheimer’s Disease and Related Dementias!

Deadline Aug 15th

https://t.co/WBbLM2Dvde

[Eric Topol @EricTopol]

Very concerning about the new drug w/modest effects for Alzheimer's disease (AD)
"If the patient hadn’t been on lecanemab she would be alive today.”
Underlying cerebral amyloid angiopathy is present in nearly half of AD patients
https://t.co/UNRoKcICNw @cpiller @ScienceMagazine

[Willa D Brenowitz @WillaBrenowitz]

Excited our Perspective on the importance of observational studies in AD and dementia research is out! With @KristineYaffe @UCSFpopbrain @UCSF #alzheimerdisease #epitwitter

[Nat Rev Neurology @NatRevNeurol]

New online! Observational studies in Alzheimer disease: bridging preclinical studies and clinical trials https://t.co/xbMr1yiyTX

[Nat Rev Neurology @NatRevNeurol]

New online! Ventricular enlargement caused by aducanumab https://t.co/d3gOc6I7yT

[Bonnielin Swenor PhD @BonnieSwenorPhD]

To my disability community and allies - @NIH is asking for public feedback on two Requests for Information (RFI) that impact the disability community. Please consider responding. Links are below. (1/7)

[Maria Glymour @MariaGlymour]

Please take the time to comment. The CMS decision was brave - a step towards finding answers that will help people living the reality of AD instead of the magical thinking that if we hope hard enough, it must be true. #aduhelm #FindOutIfItWorks.

[Willa D Brenowitz @WillaBrenowitz]

@ManlyEpic Congratulations!!!!!!!!!!🎉🎊

[Willa D Brenowitz @WillaBrenowitz]

@UCSFpopbrain @nbcsnl Our research made it to SNL?!!
Depressive Symptoms Imputed Across the Life Course Are Associated with Cognitive Impairment and Cognitive Decline https://t.co/Ry5D0qfgjg

with @KristineYaffe @AdinaHazzouri Eric Vittinghoff @GoldenSherita Annette Fitzpatrick @UCSFpopbrain

[Willa D Brenowitz @WillaBrenowitz]

Check out our paper at DOI: 10.3233/JAD-210588

[Willa D Brenowitz @WillaBrenowitz]

Excited our work on depressive symptoms and cognitive impairment was highlighted by @sfchronicle!

We imputed depressive symptoms in younger ages from a pooled cohort; highlights need for further lifecourse studies on depression and brain aging @KristineYaffe @AdinaHazzouri

[San Francisco Chronicle @sfchronicle]

The risk of dementia is 73% higher for people with these symptoms in early adulthood: https://t.co/c5lhBESPtZ

[Madhav Thambisetty @MadhavThambiset]

Why do amyloid lowering Rx accelerate brain atrophy? #Donanemab "accelerated brain volume loss in the TRAILBLAZER-ALZ trial. This cannot be attributed to reduction in plaque volume" Surely this can't be a desirable effect of "effective" Rx? https://t.co/i40a4yGhik @ProfRobHoward

[Lon S. Schneider, MD @LonSchneiderMD]

Instead of grousing you’ve got til Aug 11 to comment on aducanumab Aduhelm to CMS. You can do it now.
National Coverage Analysis (NCA) Tracking Sheet for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (CAG-00460N) https://t.co/Ywbld3K0XN

[Yue Leng @YueLengsleep]

I'm thrilled to share that we are recruiting for SleepTIGHT ! DM 👉if you are suffering from sleep problems &memory loss & like to try a FDA-approved digital sleep therapeutic for FREE! #insomnia #clinicaltrial @UCSFPsychiatry @UCSF_Epibiostat @UCSFGeriatrics @GBHI_Fellows

[Maria Glymour @MariaGlymour]

I don't understand the reasoning that approving a potentially ineffective drug is a big success, or that providing billions in profit for a potentially ineffective or even harmful drug will stimulate the type of innovation we're hoping for. Seems circular. #aducanumab

[Willa D Brenowitz @WillaBrenowitz]

Interested in instrumental variable approaches including Mendelian randomization? Come check out our session! #SER2021 Fri June 25 10:15-11:45am MT

Featuring talks by @c_lowenstein, Elizabeth Diemer, Eric Tchetgen Tchetgen, and discussion by @MariaGlymour
#EpiTwitter

[SER @societyforepi]

Can instrumental variables become a core tool for health research? Join session chair @WillaBrenowitz in a discussion of cross-disciplinary perspectives on IVs and their utility to improve understanding of causes of poor health Jun 25 @ 10:15 am – 11:45 am MT. #SER2021

[Chris Lowenstein @c_lowenstein]

Excited to join #SER2021 to present work w/ @justinswhite @WilliamHDow on IV methods to study peer effects in health behaviors. Tune in for great content on identification, inference & more from Elizabeth Diemer, Eric Tchetgen Tchetgen @WillaBrenowitz & discussant @MariaGlymour!

[Robert Howard @ProfRobHoward]

The FDA's reasoning and procedures over the scientifically inexplicable approval of aducanumab just get murkier with reading of these further documents. Most telling has to be that their internal statisticians have consistently opposed approval at all stages.